Skip to Main Content
DownloadHi-Res Photo

Renelle Lim, MD

Assistant Professor of Ophthalmology and Visual Science

Contact Information

Renelle Lim, MD

Related Links

Yale Medicine

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Research Summary

Dr. Lim trained with the renowned ophthalmologic oncologist Carol Shields at Wills Eye, and her publications within the last 3 years include reports related to ocular metastases, ocular oncocytoma, genomics of choroidal melanoma, an other reports related to ocular melanoma. She participates in clinical activities of Yale Cancer Center, teaches ocular oncology to the ophthalmology house staff, and continues to contribute to the field of ophthalmologic oncology.

Research Interests

Diagnostic Techniques, Ophthalmological; Medical Oncology; Neoplasm Metastasis; Pediatrics

Clinical Trials

ConditionsStudy Title
CervixA Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
Phase IA Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1
LungA Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN) Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Corpus UteriA Phase II Evaluation of the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Persistent or Recurrent Endometrial Cancer
Phase IA Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
Breast - Female; Phase IA Phase II Multiple-Arm, Open-Label, Randomized Study of PARP Inhibition (Veliparib; ABT-888) and Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) Either Alone or in Combination in Homologous DNA Repair (HDR) Deficient Triple Negative Breast Cancer (TNBC)
Edit Profile